RE:RE:RE:Anyone feeling good about Wednesday? PLWH and suffering from Lipodistrophy and taking Egrifta are still a substantial low hanging fruit especially as prevention of Nash .... no FDA approval and no label change needed just increased awareness of increased risk of Nash with lipo
Wino115 wrote: The current investment case for anyone holding shares is that they need to show the ongoing revenue growth has continued and the $90-95mil target is "reasonable". Showing another year of 15% revenue growth will start the process of showing the underlying fundamentals are intact, but were hidden by RD spend and budget drift, which they are reversing.
As we heard last call, they've been chastised by the market reaction and know the driver they can influence is more sales, cash breakeven, and profits. This is something they can do in relatively short order given RD expense falls off a cliff in 2H and becomes only what they need to spend. If they can show that, it can at least begin healing the wound of the oncology trial set back. Then you can at least make a case that a company growing 15% with $80m,$90+mil, $100+mil and profits next year should be worth an average growing biotech multiple which would start the process of seeing the share get to the U$1.50-$2 level and then to $3ish.
They will update on the other assets but we know unless something amazing has happened they will take a bit more time to get to the point where they might be able to add value with them. The one thing that could go a bit quicker than anyone thinks could be if they can get someone interested in the work they've done around the combo's (carboplatin, PD-L1, anti-metastatic). It's too early to hear anything about partners, but it sure would be nice to understand how they see those developments and what they think is the best way to capitalize on that research. If the other PDC companies can find partners to take lab-bench results to a trial, they ought to be able to and those results don't really rely on the TH1902 trial data - they are standalone developments to some extent. They obviously rely on the PDC part and the fact taxol is the bomb. But combo data is very different than mono data as far as if you want to trial it with your drug. Both Bicycle and Cybrexa got partners to take their lab results to a trial. That would be a huge confidence booster to the company and the SORT1 platform -frankly, massive given where they are. So while there can't be anything substantive to talk about, hearing how they see this and their strategy to parlay the science would be very valuable and could just breathe some life into the stock again.
Let's see what we hear, but just decent financials will be a great starting point to start to heal the wound we've all suffered.